Supplementary Figure 1

Different factors that promote and/or inhibit NED in PC.

Influence of CSCs, EMT, and NE transcriptomes on NED in PC. Each pathway affecting NED is further systematically classified according to the type of experiment (cell lines, patients, mice models).

Supplementary Figure 2

Autophagy related pathways and targets that promote and/or inhibit NED in PC.

Influence of various miRNAs, PI3K-AKT-mTOR pathway, Ca^{2+} channel, AMPK, and PIK3CA on NED in PC. Each pathway affecting NED is further systematically classified according to the type of experiment (cell lines, patients, mice models).


A. Neuroendocrine differentiation in PC cell lines (PC3, DU145, NCI-H660, LNCaP, C4-2B, C4-2, etc)
B. Neuroendocrine differentiation in PC patients (HRPC, t-NEPC, ADPC, CRPC-nonNE, CRPC-NE+, NEPC, etc)
C. Neuroendocrine differentiation in mice model (PDX, CDX, TRAMP, Pten, etc)
IL-6 ⊣ REST → A
Knock-down of GSN ⊣ IL-6 ⊣ A
GRP78/SPARC/IL6 → A, B, C
IL-6 → p38MAPK → TGF-β/SMAD2 → A
IL-6 → VEGF → A, B
WLS-WNT → A, B, C
Icaritin ⊣ IL-6/STAT3 and Aurora kinase A pathways ⊣ A, C
Activation ALK/N-Myc → WNT/β-Catenin → A, C
FOXB2 → WNT → A, B
WNT4/TCF7L1 → A, B, C
N-Myc → EZH2 → A, B, C
AURKA/MYCN → B
N-Myc and AURKA → C
miR-145-5p ⊣ SOX11/MYCN ⊣ A, B, C
MYCN-PARP-DDR → A, B, C
FSCN1 → N - Myc → A, B
MUC1-C → MYC→BRN2 pathway → A, B
SOX2 → A, B, C
TBX2/miR-200c-3p/SOX2/N-MYC → A, B, C
LIN28B/let-7/SOX2 → A, B, C
CD44 → A, B
CD133 → B, C
NRP2/VEGFR2 → STAT3 phosphorylation and subsequently SOX2 → A, B, C
miR-194 ⊣ FOXA1
Inhibition miR-194 ⊣ A, B
FOXA1 → A, B, C
FOXA2 → A, B, C
FOXA1 ⊣ A, B, C
PHF8 → FOXA2 → A, B, C
FOXA2 → KIT → A, B, C
p38MAPK → FOXC2 → A, B, C
Loss of FOXA2 → Mash1 → B
BRN4/BRN2 → A, B
Over-expression BRN2 → A, B, C
miR-25 and FBXW7 → AURKA → A, B
DLL3 → A, B, C
PSCA → B
PEG10 → A, B, C
ASCL1 and CEACAM5 → A, B, C


A. Neuroendocrine differentiation in PC cell lines (PC3, DU145, NCI-H660, LNCaP, C4-2B, C4-2, etc)
B. Neuroendocrine differentiation in PC patients (HRPC, t-NEPC, ADPC, CRPC-nonNE, CRPC-NE+, NEPC, etc)
C. Neuroendocrine differentiation in mice model (PDX, CDX, TRAMP, Pten, etc)
Downregulation PKCλ/ι
upregulation mTORC1/ATF4
A, B, C
MAOA/mTOR/HIF-1α
A, C
PI3K-Akt/mTOR/MAPK
A, B
mTOR
IRF1
A, C
ZFPL1
PI3K-AKT
A, B
miR-17/20b/106b
AKT3
A, B
MIF
AKT and ERK1/2
A
AKT1 inhibition
miR669h-3p/3104-3p
miR375-3p/let7a/10a-5p
C
GHRH-induced stimulation
Calcium channel activation
A
High glucose
Cav3.2
A
H2S/Cav3.2
A
Disruption of AR
T-type Ca2+ channel
A
AMPK-SIRT1-p38MAPK
A
Calcium-Sensing Receptor
A, B, C
Downregulation miR-17
CCND1
A
Cannabinoid WIN 55,212-2
AMPK
A
Downregulated miR-143
B
Overexpression of miR-17/miR-20a/miR-106a/miR-106b
A
Protocadherin-PC
A, B
LIN28B/miRNA-let-7/SOX2
A, B, C
TRIM36
glycolysis
ferroptosis
GPx4
A, B
Loss of YAP1
INSM1
A, B
PIK3CA
B
YAP1
B, C
Inhibition of REST and p53
A, B, C